Domov › Non-Hodgkinov limfom › Texas
Klinične študije za Non-Hodgkinov limfom v Texas
48 študij za Non-Hodgkinov limfom išče udeležence na lokacijah v Texas.
Mesta v Texas
Uradno besedilo študije (angleško)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Md Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT05006716Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT04728893Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 12–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06176690Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Do 75 let · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT01853631CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 12–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT02917083Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
Vključevanje udeležencevOpazovalna študija
Starost 0–38 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06131801T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06343311TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- The University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 2
Starost 12 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT02693535A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Texas Southwestern, Dallas
- MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07226843A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Md Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT07195916Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
Vključevanje udeležencevFaza 1
Starost 18–100 · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06137144Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Austin
- Research Site, Houston
- Research Site, San Antonio
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT06526793Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Baylor Scott & White Health, Temple
- Texas Oncology - Gulf Coast, The Woodlands
- Texas Oncology- Northeast Texas, Tyler
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT06806033Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT03666000TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- The University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07082803A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT06393738Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT05826535Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Vključevanje udeležencevFaza 1/2
12 Months – 30 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04851119A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Lumi Research, Kingwood
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05254743Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
- Natera, Inc., Austin
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT07750886Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1/2
Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- UT Southwestern Medical Center, Dallas
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 4. avg. 2026 · NCT07188558Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 2
Starost 15–80 · Vsi spoli · Posodobljeno 30. jul. 2026 · NCT02727803DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- in še 5
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT01351545EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- in še 1
Vključevanje udeležencevFaza 1
Vse starosti · Vsi spoli · Posodobljeno 25. jun. 2026 · NCT04664179IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
- University of Texas Southwestern Medical Center, Dallas
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 8. maj 2026 · NCT06768905Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
- M D Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT05529069Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1
Starost 13 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 16. apr. 2026 · NCT03328078Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Vključevanje udeležencevFaza 1
Vse starosti · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT01555892A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 4
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT06876662Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 13. feb. 2026 · NCT05544019A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- UT Southwestern Medical Center, Dallas
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 4. feb. 2026 · NCT05892718Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Ut Southwestern, Dallas
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 22. jan. 2026 · NCT06357754AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 10. dec. 2025 · NCT05602363Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.